These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

234 related articles for article (PubMed ID: 30703770)

  • 41. Topotecan-carboplatin-etoposide combination as 1st line treatment in patients with small cell lung cancer.
    Zarogoulidis K; Mylonaki E; Kakavelas P; Zarogoulidis P; Tsiouda T; Rapti E; Lithoxopoulou H; Zarogoulidou V; Kontakiotis T;
    Lung Cancer; 2009 Nov; 66(2):226-30. PubMed ID: 19321222
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Multicentre phase II study of cisplatin-etoposide chemotherapy for advanced large-cell neuroendocrine lung carcinoma: the GFPC 0302 study.
    Le Treut J; Sault MC; Lena H; Souquet PJ; Vergnenegre A; Le Caer H; Berard H; Boffa S; Monnet I; Damotte D; Chouaid C
    Ann Oncol; 2013 Jun; 24(6):1548-52. PubMed ID: 23406729
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Bevacizumab plus capecitabine in patients with progressive advanced well-differentiated neuroendocrine tumors of the gastro-intestinal (GI-NETs) tract (BETTER trial)--a phase II non-randomised trial.
    Mitry E; Walter T; Baudin E; Kurtz JE; Ruszniewski P; Dominguez-Tinajero S; Bengrine-Lefevre L; Cadiot G; Dromain C; Farace F; Rougier P; Ducreux M
    Eur J Cancer; 2014 Dec; 50(18):3107-15. PubMed ID: 25454413
    [TBL] [Abstract][Full Text] [Related]  

  • 44. [Poorly-differentiated neuroendocrine carcinoma of ascending colon with liver metastases successfully treated with carboplatin and etoposide].
    Akiyama S; Niitani T; Narasaka T; Ohto T; Gamoh M
    Gan To Kagaku Ryoho; 2011 Jul; 38(7):1209-12. PubMed ID: 21772114
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Paclitaxel, carboplatin, and extended-schedule oral etoposide for small-cell lung cancer.
    Hainsworth JD; Hopkins LG; Thomas M; Greco FA
    Oncology (Williston Park); 1998 Jan; 12(1 Suppl 2):31-5. PubMed ID: 9516609
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Treatment with cisplatin and etoposide in patients with neuroendocrine tumors.
    Fjällskog ML; Granberg DP; Welin SL; Eriksson C; Oberg KE; Janson ET; Eriksson BK
    Cancer; 2001 Sep; 92(5):1101-7. PubMed ID: 11571721
    [TBL] [Abstract][Full Text] [Related]  

  • 47. [Neuroendocrine tumors: analysis of 252 cases].
    Chi YH; Jiang WC; Du F; Sun YK; Song Y; Yang L; Zhou AP; Wang JW
    Zhonghua Zhong Liu Za Zhi; 2013 Jan; 35(1):67-70. PubMed ID: 23648305
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Carboplatin plus oral etoposide in elderly patients with advanced non small cell lung cancer. A phase II study.
    Gridelli C; Rossi A; Scognamiglio F; Guida C; Fiore F; Gatani T; Scoppa G; Pergola M
    Anticancer Res; 1997; 17(6D):4755-8. PubMed ID: 9494602
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Second-line treatment and prognostic factors in neuroendocrine carcinoma: the RBNEC study.
    Hadoux J; Walter T; Kanaan C; Hescot S; Hautefeuille V; Perrier M; Tauveron I; Laboureau S; Do Cao C; Petorin C; Blanchet O; Faron M; Leteurtre E; Rousselet MC; Joubert Zakeyh J; Marchal A; Chatelain D; Beaulaton C; Hervieu V; Lombard-Bohas C; Ducreux M; Scoazec JY; Baudin E; ;
    Endocr Relat Cancer; 2022 Oct; 29(10):569-580. PubMed ID: 35920609
    [TBL] [Abstract][Full Text] [Related]  

  • 50. A German multicenter, randomized phase III trial comparing irinotecan-carboplatin with etoposide-carboplatin as first-line therapy for extensive-disease small-cell lung cancer.
    Schmittel A; Sebastian M; Fischer von Weikersthal L; Martus P; Gauler TC; Kaufmann C; Hortig P; Fischer JR; Link H; Binder D; Fischer B; Caca K; Eberhardt WE; Keilholz U;
    Ann Oncol; 2011 Aug; 22(8):1798-804. PubMed ID: 21266516
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Retrospective study on mixed neuroendocrine non-neuroendocrine neoplasms from five European centres.
    Frizziero M; Wang X; Chakrabarty B; Childs A; Luong TV; Walter T; Khan MS; Morgan M; Christian A; Elshafie M; Shah T; Minicozzi A; Mansoor W; Meyer T; Lamarca A; Hubner RA; Valle JW; McNamara MG
    World J Gastroenterol; 2019 Oct; 25(39):5991-6005. PubMed ID: 31660035
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Results of paclitaxel (day 1 and 8) and carboplatin given on every three weeks in advanced (stage III-IV) non-small cell lung cancer.
    Yumuk PF; Turhal NS; Gumus M; Hatabay NF; Turken O; Ozkan A; Salepci T; Aliustaoglu M; Ahiskali R
    BMC Cancer; 2005 Jan; 5():10. PubMed ID: 15667664
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Treatment of poorly differentiated neuroendocrine tumours with etoposide and cisplatin.
    Mitry E; Baudin E; Ducreux M; Sabourin JC; Rufié P; Aparicio T; Aparicio T; Lasser P; Elias D; Duvillard P; Schlumberger M; Rougier P
    Br J Cancer; 1999 Dec; 81(8):1351-5. PubMed ID: 10604732
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Chemotherapy for small cell lung carcinoma: the Greenlane Hospital experience 1993-1995.
    Lee YC; McCrystal MR; Christmas TI
    N Z Med J; 1998 Nov; 111(1078):451-2, 453-4. PubMed ID: 9891564
    [TBL] [Abstract][Full Text] [Related]  

  • 55. FOLFIRI regimen: an effective second-line chemotherapy after failure of etoposide-platinum combination in patients with neuroendocrine carcinomas grade 3.
    Hentic O; Hammel P; Couvelard A; Rebours V; Zappa M; Palazzo M; Maire F; Goujon G; Gillet A; Lévy P; Ruszniewski P
    Endocr Relat Cancer; 2012 Dec; 19(6):751-7. PubMed ID: 22940375
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Is carboplatin and oral etoposide an effective and feasible regimen in patients with small cell lung cancer?
    Pfeiffer P; Sørensen P; Rose C
    Eur J Cancer; 1995; 31A(1):64-9. PubMed ID: 7695981
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Amrubicin monotherapy for patients with extrapulmonary neuroendocrine carcinoma after platinum-based chemotherapy.
    Nio K; Arita S; Isobe T; Kusaba H; Kohashi K; Kajitani T; Tamura S; Hirano G; Mitsugi K; Makiyama A; Esaki T; Ariyama H; Oda Y; Akashi K; Baba E
    Cancer Chemother Pharmacol; 2015 Apr; 75(4):829-35. PubMed ID: 25702050
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Five-day oral etoposide treatment for advanced small-cell lung cancer: randomized comparison with intravenous chemotherapy.
    Souhami RL; Spiro SG; Rudd RM; Ruiz de Elvira MC; James LE; Gower NH; Lamont A; Harper PG
    J Natl Cancer Inst; 1997 Apr; 89(8):577-80. PubMed ID: 9106647
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Amrubicin Monotherapy for Patients with Platinum-Pretreated Non-Gastrointestinal Non-Pancreatic Extrapulmonary Neuroendocrine Carcinoma.
    Ebata T; Shimoi T; Ishiwata T; Iwasawa S; Bun S; Yunokawa M; Yonemori K; Takiguchi Y; Tamura K
    Oncology; 2017; 93(3):177-182. PubMed ID: 28521313
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Prolonged oral versus high-dose intravenous etoposide in combination with carboplatin for stage IV non-small-cell lung cancer (NSCLC): a randomized trial.
    Jeremic B; Shibamoto Y; Milicic B; Milisavljevic S; Nikolic N; Dagovic A; Aleksandrovic J; Radosavljevic-Asic G
    Lung Cancer; 1999 Sep; 25(3):207-14. PubMed ID: 10512132
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.